1
|
Montastruc G, Benevent J, Rousseau V, Chebane L, Bondon-Guitton E, Durrieu G, Montastruc J, Montastruc F, Sommet A. Statins and diabetes: Are all statins at risk? A pharmacoepidemiological study. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol 2017; 11:549-52. [PMID: 26891968 DOI: 10.1007/s11523-016-0417-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Over the past few years, data have suggested that severe peripheral arterial occlusive disease (PAOD) is associated with nilotinib exposure. However, the characteristics of this adverse drug reaction are poorly described since its frequency is low. As far as we know, no study using a spontaneous adverse drug reactions reporting system was performed to describe the characteristics of cases of PAOD related to nilotinib. OBJECTIVE We performed a study to describe the cardiovascular risk profile of cases of PAOD in patients treated with nilotinib spontaneously reported to the French Pharmacovigilance Database (FPVD). PATIENTS/METHODS We selected all cases of "vascular disorders," as the System Organ Class in MedDRA®, in which nilotinib was "suspected" and recorded in the French Pharmacovigilance Database between 2007 and 21 October 2014. We then identified cases of PAOD with a Low Level Term and through a detailed summary of the clinical description. RESULTS We identified 25 cases of POAD. Most of the patients were older than 60 years (84 %) or had another cardiovascular risk factor such as hypercholesterolemia, arterial hypertension, overweight/obesity, smoking, or diabetes mellitus (72 %). Females (13 cases) and males (12 cases) were equally represented, but the presence of cardiovascular risk factors was more frequent in females than in males. The mean time from initiation of nilotinib to PAOD onset was 24 months and was significantly longer in patients aged less than 60 years compared with those aged over 60 years (33.8 ± 24.6 months vs. 22.6 ± 17.5 months, p = 0.002). Pre-existing cardiovascular risk factors, especially diabetes mellitus, also seem to accelerate its occurrence. CONCLUSIONS The FPVD is a useful tool in describing the cardiovascular risk profile of patients with PAOD during nilotinib exposure. Physicians have to be particularly vigilant in patients older than 60 years of age; in patients younger than 60 years of age, long-term surveillance has to be maintained.
Collapse
Affiliation(s)
- E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France.
| | - S Combret
- Centre Régional de Pharmacovigilance de Bourgogne, Centre Hospitalier Universitaire, Dijon, France
| | - M C Pérault-Pochat
- Pharmacologie Clinique et Vigilances, Centre Hospitalier Universitaire, Poitiers, France
| | - M Stève-Dumont
- Centre Régional de Pharmacovigilance, Hôpital de Cimiez, Nice, France
| | - H Bagheri
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - F Huguet
- Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France
| | - F Despas
- Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - A Pathak
- Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l'Université de Toulouse, Toulouse, France
| |
Collapse
|
3
|
Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. [Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database]. Rev Med Interne 2016; 38:340-343. [PMID: 27745936 DOI: 10.1016/j.revmed.2016.07.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 06/07/2016] [Accepted: 07/30/2016] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. CASE REPORT We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus. CONCLUSION Despite an excellent tolerance and high efficacy-side effect ratio, this case report adds some evidence for an otoxicity of hydroxychloroquine.
Collapse
Affiliation(s)
- J-N Chatelet
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - M Auffret
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France.
| | - S Combret
- Centre régional de pharmacovigilance de Dijon, CHU de Dijon, 21079 Dijon cedex France
| | - E Bondon-Guitton
- Centre régional de pharmacovigilance de Toulouse, CHU de Toulouse, 31000 Toulouse France
| | - M Lambert
- Service de médecine Interne, hôpital Claude-Huriez, CHRU de Lille, 59045 Lille cedex France
| | - S Gautier
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France
| |
Collapse
|
4
|
Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study. Pharmacol Res 2016; 118:119-120. [PMID: 27265115 DOI: 10.1016/j.phrs.2016.05.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 05/24/2016] [Accepted: 05/25/2016] [Indexed: 10/21/2022]
Affiliation(s)
- A Cabarrot
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France.
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - L Chebane
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - V Rousseau
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - F Moulis
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - G Durrieu
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - H Bagheri
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| | - F Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Centre Hospitalier Universitaire, Faculté de Médecine de Toulouse, France
| |
Collapse
|
5
|
Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther 2016; 41:360-361. [PMID: 27009771 DOI: 10.1111/jcpt.12383] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 03/01/2016] [Indexed: 12/01/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. CASE DESCRIPTION The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. WHAT IS NEW AND CONCLUSION Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
Collapse
Affiliation(s)
- G Tournaire
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - F Despas
- Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - F Huguet
- Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France
| | - J L Montastruc
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - E Bondon-Guitton
- Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| |
Collapse
|
6
|
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132:31-4. [DOI: 10.1016/j.anorl.2014.11.001] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Durrieu G, Batz A, Rousseau V, Bondon-Guitton E, Petiot D, Montastruc JL. Use of administrative hospital database to identify adverse drug reactions in a Pediatric University Hospital. Eur J Clin Pharmacol 2014; 70:1519-26. [PMID: 25304009 DOI: 10.1007/s00228-014-1763-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Accepted: 09/29/2014] [Indexed: 10/24/2022]
Abstract
PURPOSE The aim of the study was to detect adverse drug reactions (ADRs) in pediatric inpatients using the medical administrative database "Programme de Médicalisation des Systèmes d'Information" (PMSI) and to compare these cases ADRs with those spontaneously reported to a regional PharmacoVigilance (PV) Centre. METHODS The study was conducted from January 2008 to December 2011 in the Children University Hospital of Toulouse (Midi-Pyrénées, South-west France). From PMSI database, all discharge summaries including selected ICD-10 codes (10th International Classification of Diseases) were analyzed. All ADRs spontaneously reported by the Children Hospital of Toulouse and registered in the French PV Database (FPVDB) were included. The capture-recapture method was applied to estimate the incidence of ADRs. RESULTS During the study period, we identified 60 reports from the PMSI database and 200 from the FPVDB. The rate of "serious" ADRs was higher in PMSI reports (74.6 % vs 38.9 %, p < 0.0001). The most frequent ADRs reported were musculoskeletal (12.4 %) and central (11.3 %) ADRs in PMSI database versus cutaneous (22.4 %) and general (17.5 %) ADRs in FPVDB. The most frequently suspected drugs were antineoplastic drugs (31.1 %) in PMSI database versus anti-infectives (38.2 %) in FPVDB. The estimated number of ADRs was 717 [95 % confidence interval (CI) 513, 921], and the incidence of ADRs among admissions was 0.6 % (95 % CI 0.4, 0.8). CONCLUSIONS Use of PMSI database improves from around 30 % detection of ADRs in children. In comparison with classical pharmacovigilance database, it also allows to detect different ADRs and drugs, thus enhancing safe medicine use for pediatric patients.
Collapse
Affiliation(s)
- G Durrieu
- Department of Medical and Clinical Pharmacology, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Toulouse University Hospital, Toulouse, France,
| | | | | | | | | | | |
Collapse
|
8
|
Pechchamanann V, Gries C, Bondon-Guitton E, Pourcel L, Lapeyre-Mestre M, Roussin A. Facteurs associés à la survenue d’une anémie chez des patients VIH et co-infectés VIH–VHC : étude cas-témoin intracohorte. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Bondon-Guitton E, Sommet A, Montastruc J. Confusion, a Rather Serious Adverse Drug Reaction with Valproic Acid: A Review of the French Pharmacovigilance Database. Pharmacopsychiatry 2009; 42:61-5. [DOI: 10.1055/s-0028-1102912] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|